ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
11.18
-0.14 (-1.24%)
Dec 20, 2024, 4:00 PM EST - Market closed
ARS Pharmaceuticals Employees
As of December 31, 2023, ARS Pharmaceuticals had 26 total employees, including 24 full-time and 2 part-time employees. The number of employees increased by 6 or 30.00% compared to the previous year.
Employees
26
Change (1Y)
6
Growth (1Y)
30.00%
Revenue / Employee
$98,769
Profits / Employee
-$1,888,615
Market Cap
1.09B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 3,930 |
| Establishment Labs Holdings | 908 |
| Weave Communications | 844 |
| CareDx | 643 |
| ANI Pharmaceuticals | 642 |
| Ardelyx | 267 |
| Syndax Pharmaceuticals | 184 |
| Innoviva | 112 |
SPRY News
- 2 days ago - ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - GlobeNewsWire
- 9 days ago - ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia - GlobeNewsWire
- 17 days ago - ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 - Benzinga
- 5 weeks ago - ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States - GlobeNewsWire
- 6 weeks ago - ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) - GlobeNewsWire